Cynapsus Therapeutics Inc. (CYNAF) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Cynapsus Therapeutics Inc.
Fiscal year is January-December. All values CAD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 13,586 14,926 13,872 60,988 61,036
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 13,586 14,926 13,872 60,988 61,036
Depreciation - - 2,762 2,002 2,050
Amortization of Intangibles - - 11,110 58,986 58,986
Gross Income (13,586) (14,926) (13,872) (60,988) (61,036)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 1.98M 1.79M 2.23M 2.52M 5.76M
Research & Development 616,297 454,027 907,483 814,716 1.63M
Other SG&A 1.36M 1.34M 1.32M 1.71M 4.13M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 (230,688) 0 (225,263) (1.15M)
EBIT after Unusual Expense 0 230,688 0 225,263 1.15M
Non Operating Income/Expense 230,468 135,780 37,673 398,507 423,859
Non-Operating Interest Income 12,865 1,015 0 - -
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 0 0 639,920 1.1M 187,975
Gross Interest Expense 0 0 639,920 1.1M 187,975
Interest Capitalized 0 0 0 0 0
Pretax Income (1.75M) (1.44M) (2.85M) (3.06M) (4.43M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 0
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (1.75M) (1.44M) (2.85M) (3.06M) (4.43M)
Minority Interest Expense 0 0 0 0 0
Net Income (1.75M) (1.44M) (2.85M) (3.06M) (4.43M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (1.75M) (1.44M) (2.85M) (3.06M) (4.43M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (1.75M) (1.44M) (2.85M) (3.06M) (4.43M)
EPS (Basic) (0.20) (0.20) (0.30) (0.22) (0.13)
Basic Shares Outstanding 8.16M 9.12M 10.2M 13.65M 34.67M
EPS (Diluted) (0.20) (0.20) (0.30) (0.22) (0.13)
Diluted Shares Outstanding 8.16M 9.12M 10.2M 13.65M 34.67M
EBITDA (1.98M) (1.79M) (2.23M) (2.52M) (5.76M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Cynapsus Therapeutics Inc.
Fiscal year is January-December. All values CAD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 13,586 14,926 13,872 60,988 61,036
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 13,586 14,926 13,872 60,988 61,036
Depreciation - - 2,762 2,002 2,050
Amortization of Intangibles - - 11,110 58,986 58,986
Gross Income (13,586) (14,926) (13,872) (60,988) (61,036)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 1.98M 1.79M 2.23M 2.52M 5.76M
Research & Development 616,297 454,027 907,483 814,716 1.63M
Other SG&A 1.36M 1.34M 1.32M 1.71M 4.13M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 (230,688) 0 (225,263) (1.15M)
EBIT after Unusual Expense 0 230,688 0 225,263 1.15M
Non Operating Income/Expense 230,468 135,780 37,673 398,507 423,859
Non-Operating Interest Income 12,865 1,015 0 - -
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 0 0 639,920 1.1M 187,975
Gross Interest Expense 0 0 639,920 1.1M 187,975
Interest Capitalized 0 0 0 0 0
Pretax Income (1.75M) (1.44M) (2.85M) (3.06M) (4.43M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 0
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (1.75M) (1.44M) (2.85M) (3.06M) (4.43M)
Minority Interest Expense 0 0 0 0 0
Net Income (1.75M) (1.44M) (2.85M) (3.06M) (4.43M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (1.75M) (1.44M) (2.85M) (3.06M) (4.43M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (1.75M) (1.44M) (2.85M) (3.06M) (4.43M)
EPS (Basic) (0.20) (0.20) (0.30) (0.22) (0.13)
Basic Shares Outstanding 8.16M 9.12M 10.2M 13.65M 34.67M
EPS (Diluted) (0.20) (0.20) (0.30) (0.22) (0.13)
Diluted Shares Outstanding 8.16M 9.12M 10.2M 13.65M 34.67M
EBITDA (1.98M) (1.79M) (2.23M) (2.52M) (5.76M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
